DIRECTOR OF THE JENNER INSTITUTE, LAKSHMI MITTAL & FAMILY PROFESSOR OF VACCINOLOGY, PROFESSOR OF HUMAN GENETICS
Vaccines for malaria and other major diseases
Adrian V. S. Hill KBE, FRCP, FRS is the Lakshmi Mittal Professor of Vaccinology and Director of the Jenner Institute at Oxford University. In 2005 he founded the Jenner Institute at Oxford, which is now one of the largest academic vaccine centres globally with clinical-stage vaccine programmes against fifteen diseases.
His current lead malaria vaccine, R21 in matrix-M adjuvant, has shown high efficacy in clinical trials in the UK and Africa (Lancet. 2021;397:1809-1818) and could be the first widely used vaccine to impact on the great disease burden of malaria in Africa.
In Q1 2020, the Jenner Institute initiated a major effort towards rapid development of a COVID-19 vaccine which in collaboration with AstraZeneca is now in world-wide pandemic deployment.
He has published over 600 research papers with 60,000 citations and co-founded several spin-off companies. He is a Fellow of the UK Academy of Medical Sciences, the Royal College of Physicians and the Royal Society.
An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease.
Dold C. et al, (2023), Science translational medicine, 15
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
Jenkin D. et al, (2023), The Lancet. Infectious diseases
Higher antigen occupancy of high avidity CSP serum antibodies associates with protection against human malaria
Li K. et al, (2023), Biophysical journal, 122, 144a - 145a
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209
A tool for evaluating heterogeneity in avidity of polyclonal antibodies.
Li K. et al, (2023), Frontiers in immunology, 14